-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, CRISPR Therapeutics Reports 83% Of Systemic Sclerosis Patients Achieved rCRISS-25 Response At Month 3 With Zugo-Cel, As All Nine Myositis Patients Achieve Moderate Or Major TIS Response

Benzinga·11/09/2026 08:11:04
Listen to the news
  • Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response
  • Zugo-cel has been well tolerated in all 21 patients dosed to date, with no cytokine release syndrome (CRS) above Grade 2 and no immune effector cell-associated neurotoxicity syndrome (ICANS) or immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS)
  • All nine patients with idiopathic inflammatory myopathy (IIM) achieved a moderate or major Total Improvement Score (TIS) response